U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H21F3N4O3S
Molecular Weight 430.445
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RONICICLIB

SMILES

C[C@@H](O)[C@@H](C)OC1=NC(NC2=CC=C(C=C2)[S@](=N)(=O)C3CC3)=NC=C1C(F)(F)F

InChI

InChIKey=UELYDGOOJPRWGF-SRQXXRKNSA-N
InChI=1S/C18H21F3N4O3S/c1-10(26)11(2)28-16-15(18(19,20)21)9-23-17(25-16)24-12-3-5-13(6-4-12)29(22,27)14-7-8-14/h3-6,9-11,14,22,26H,7-8H2,1-2H3,(H,23,24,25)/t10-,11-,29+/m1/s1

HIDE SMILES / InChI

Molecular Formula C18H21F3N4O3S
Molecular Weight 430.445
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Roniciclib (BAY1000394) is a pan-cyclin-dependent kinase inhibitor that has been developed for treatment in small cell lung carcinoma and solid tumors. Roniciclib targets certain key proteins that are essential for the survival of cancer cells, resulting in decreased tumor growth. Phase I studies to evaluate the safety, tolerability and pharmacokinetics of roniciclib have been completed successfully. In phase II studies, roniciclib was found to be well tolerated and showed promising efficacy when combined with chemotherapy in small cell lung carcinoma patients. However, due to an observed safety signal (treatment-emergent adverse events) in one phase II study, other clinical trials have been discontinued and further development of roniciclib was terminated.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
7.0 nM [IC50]
9.0 nM [IC50]
11.0 nM [IC50]
5.0 nM [IC50]
PubMed

PubMed

TitleDatePubMed
BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.
2012 Oct
Patents

Patents

Substance Class Chemical
Created
by admin
on Sat Dec 16 05:09:29 GMT 2023
Edited
by admin
on Sat Dec 16 05:09:29 GMT 2023
Record UNII
0W9Q8U337A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RONICICLIB
INN   WHO-DD  
INN  
Official Name English
BAY1000394
Code English
BAY10-00394
Code English
BAY-1000394
Code English
2-BUTANOL, 3-((2-((4-((S(R))-S-CYCLOPROPYLSULFONIMIDOYL)PHENYL)AMINO)-5-(TRIFLUOROMETHYL)-4-PYRIMIDINYL)OXY)-, (2R,3R)-
Common Name English
roniciclib [INN]
Common Name English
(R)-S-CYCLOPROPYL-S-(4-((4-(((1R,2R)-2-HYDROXY-1-METHYLPROPYL)OXY)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL)AMINO)PHENYL)SULFOXIMIDE
Systematic Name English
Roniciclib [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2185
Created by admin on Sat Dec 16 05:09:29 GMT 2023 , Edited by admin on Sat Dec 16 05:09:29 GMT 2023
NCI_THESAURUS C129825
Created by admin on Sat Dec 16 05:09:29 GMT 2023 , Edited by admin on Sat Dec 16 05:09:29 GMT 2023
Code System Code Type Description
SMS_ID
100000174947
Created by admin on Sat Dec 16 05:09:29 GMT 2023 , Edited by admin on Sat Dec 16 05:09:29 GMT 2023
PRIMARY
PUBCHEM
71494949
Created by admin on Sat Dec 16 05:09:29 GMT 2023 , Edited by admin on Sat Dec 16 05:09:29 GMT 2023
PRIMARY
FDA UNII
0W9Q8U337A
Created by admin on Sat Dec 16 05:09:29 GMT 2023 , Edited by admin on Sat Dec 16 05:09:29 GMT 2023
PRIMARY
NCI_THESAURUS
C92579
Created by admin on Sat Dec 16 05:09:29 GMT 2023 , Edited by admin on Sat Dec 16 05:09:29 GMT 2023
PRIMARY
ChEMBL
CHEMBL3544942
Created by admin on Sat Dec 16 05:09:29 GMT 2023 , Edited by admin on Sat Dec 16 05:09:29 GMT 2023
PRIMARY
CAS
1223498-69-8
Created by admin on Sat Dec 16 05:09:29 GMT 2023 , Edited by admin on Sat Dec 16 05:09:29 GMT 2023
PRIMARY
DRUG BANK
DB12974
Created by admin on Sat Dec 16 05:09:29 GMT 2023 , Edited by admin on Sat Dec 16 05:09:29 GMT 2023
PRIMARY
INN
9806
Created by admin on Sat Dec 16 05:09:29 GMT 2023 , Edited by admin on Sat Dec 16 05:09:29 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
The development of bronchopulmonary hemorrhage and sepsis resulted in the death of two patients. The study was ultimately terminated prematurely due to an unfavorable risk-benefit ratio in patients.
IC50
TARGET -> INHIBITOR
TARGET -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY